SCHEMBL2489941

SCHEMBL2489941

O=C1/C(=C\c2ccc(O)c(O)c2)SC(=S)N1c1cccc(F)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUSP26 Q9BV47 1/20 0.73
HSPD1 P10809 1/20 0.69
HSPE1 P61604 1/20 0.69
DUSP22 Q9NRW4 4/20 0.62
CFTR P13569 7/20 0.61
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
GAA P10253 2/20 0.54
POLB P06746 1/20 0.54
HSP90AA1 P07900 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
KDM4E B2RXH2 1/20 0.54
JAK2 O60674 1/20 0.54
NSD2 O96028 1/20 0.54
ALDH1A1 P00352 1/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489942 1.00 DUSP26 (0.73) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL14788077 1.00 DUSP26 (0.73) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL12123529 0.90 DUSP26 (0.60) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL14788063 0.88 HSPD1 (0.76) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL2403963 0.87 HSPD1 (0.81) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL2403957 0.87 HSPD1 (0.81) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL2403960 0.87 HSPD1 (0.81) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL5455212 0.87 HSPD1 (0.85) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL5455211 0.87 HSPD1 (0.85) DUSP26HSPD1HSPE1DUSP22CFTR
SCHEMBL12637130 0.86 DUSP26 (0.73) DUSP26HSPD1HSPE1DUSP22CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 US disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 DUSP26 2061/4885HSPD1 2879/4885HSPE1 2494/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 DUSP26 2061/4885HSPD1 2879/4885HSPE1 2494/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 DUSP26 2061/4885HSPD1 2879/4885HSPE1 2494/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 DUSP26 2061/4885HSPD1 2879/4885HSPE1 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.